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ABSTRACT 
USP6NL, also named RN-tre, is a GTPase activating protein (GAP) involved in 
control of endocytosis and signal transduction. Here we report that USP6NL is 
overexpressed in breast cancer (BC), mainly of the basal-like/integrative cluster 10 
subtype. Increased USP6NL levels were accompanied by gene amplification and 
were associated with worse prognosis in the METABRIC dataset, retaining 
prognostic value in multivariable analysis. High levels of USP6NL in BC cells 
delayed endocytosis and degradation of the epidermal growth factor receptor 
(EGFR), causing chronic AKT activation. In turn, AKT stabilized the glucose 
transporter GLUT1 at the plasma membrane, increasing aerobic glycolysis. In 
agreement, elevated USP6NL sensitized BC cells to glucose deprivation, indicating 
that their glycolytic capacity relies on this protein. Depletion of USP6NL accelerated 
EGFR/AKT downregulation and GLUT1 degradation, impairing cell proliferation 
exclusively in BC cells that harbored increased levels of USP6NL. Overall, these 
findings argue that USP6NL overexpression generates a metabolic rewiring that is 
essential to foster the glycolytic demand of BC cells and promote their proliferation. 
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INTRODUCTION 
A large fraction of BCs, especially of the basal-like subtype, display unique gene 
ontologies of growth factor signaling, glycolysis and gluconeogenesis (1) and are 
characterized by increased glycolysis and dependence on this metabolic drift for 
proliferation (2,3).   
 High rates of glucose uptake are achieved through transcriptional up regulation 
and increased targeting of GLUT1, a member of the glucose transporter family, to 
the plasma membrane (PM) (4). Localization of GLUT1 to the cell surface is largely 
regulated through its endocytic traffic (5-11), controlled, in non-transformed cells, by 
cytokine stimulation (12,13) or energy stress (6). In cancer cells, several oncogenic 
lesions, including hyper activation of the EGFR/PI3K/AKT signaling pathway, induce 
accumulation of GLUT1 at the cell surface resulting in increased aerobic glycolysis 
(14-16). However, the molecular determinants of this signaling-metabolic rewiring 
are largely unknown. 
 USP6NL is GAP protein that stimulates GTP hydrolysis on various members of 
the Rab family, thereby inhibiting endocytosis of PM receptors and retrograde Golgi 
transport (17-20). We found that USP6NL is amplified and overexpressed in a subset 
of BCs, mainly belonging to the basal-like Integrative Cluster 10 subtype. USP6NL 
overexpression correlates with worse prognosis suggesting a role in the natural 
history of the tumor. This is strengthened by data showing that functional ablation of 
USP6NL inhibits proliferation and glycolysis exclusively in BC cells harboring high 
levels of this protein.  
 Our findings argue, therefore, that USP6NL is a regulator of the crosstalk between 
signaling and metabolic pathways whose elevation causes glycolysis addiction in BC 
cells.   
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MATERIALS AND METHODS  
 
Cell cultures, silencing and constructs 
HCC70, HCC1187, H1299 (ATCC) were grown in RPMI (Sigma) with 10% FBS 
(Euroclone) and 1% glutamine. MCF10A (a gift of J.S. Brugge, Harvard Medical 
School, Boston, USA) were grown in DMEM/F12 with EGF 20 ng/ml (Peprotech), 5% 
Horse Serum, Hydrocortisone 0.5 mg/ml, Cholera Toxin 100 ng/ml and Insulin 10 
μg/ml (Sigma). HMEC (hTERT-HME1) were from ATCC and grown in DMEM/F12 
with EGF 20 ng/ml, Hydrocortisone 0.5 mg/ml, Insulin 10 μg/ml and 10% FBS. The 
genetic identity of the cell lines was confirmed by STR profiling (Cell ID, Promega), 
lastly repeated in July 2017. Cells were periodically tested for mycoplasma with 
Venor GM kit (Minerva biolabs).  
 For functional ablation experiments, equal number of cells were plated in 
presence of siRNA oligos, and a second round of transfection was repeated the day 
after on the adherent cells. Cells were harvested 48 hours later for biochemical 
experiments or counted for the “proliferation” experiments (see “cell counts”, below). 
Ablation of USP6NL was initially performed with three different oligos (Silencer 
Select oligos, Ambion, 50 pmoles; negative control: siRNA#2) using Lipofectamine 
RNAiMAX (Invitrogen). Since the three oligos yielded comparable results, oligo 
s18721 alone was subsequently employed, after confirming its specificity in rescue 
experiments.  
 Stable, inducible HCC70 and HMEC cell populations were generated by infection 
with tetracycline-inducible lentiviral vectors (pSLIK) carrying HA-tagged USP6NL or 
HA-USP6NLR150 (R150) (17,19). In these constructs, the sequence targeted by 
oligo s18721 was mutated with the Phusion Site-Directed Mutagenesis Kit (Thermo 
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Scientific) in a silencing-resistant version: 5’-TAGACAGTATAATCACGCA-3’. Stable 
populations, including MCF10A-pSLIK-RAB5A (a gift from Giorgio Scita) (21), were 
established by neomycin selection and grown in media supplemented with 10% Tet 
system-approved FBS (Clontech). Expression of USP6NL, R150 or RAB5 was 
induced by doxycycline (1 g/ml, Sigma) for 48 hours. HCC70 cells stably 
expressing PI3KCA were generated by infection with the retroviral construct pBABE 
puro Myr PIK3CA, a gift from Jean Zhao (Addgene plasmid # 12523). pLPCX-EGFP- 
myc-GLUT1 (22) was kindly provided by Jeffrey Pessin and transiently transfected 
using the X-tremeGENE reagent (Sigma). 
 
Antibodies and reagents  
Antibodies were: affinity-purified rabbit polyclonal anti-USP6NL home made; anti-
AKT (2920), anti-phosphoAKT-Ser473 (4060), anti-phosphoAKT-Thr308 (2965), anti-
phosphoGSK3-Ser9 (9336), anti-phosphoEGFR (3777), anti-phosphoMET (3077), 
Cell Signaling Technology; anti-GSK3 (E-11 sc377213), anti-HA (Y-11 sc-805; F-7 
sc-7392), anti-HSP90 (sc-13119), anti-EEA1 (N-19 sc-6415), anti-EGFR (1005 sc-
03), anti-Rab5 (D-11 sc46692), anti-MET (D-4 sc514148) Santa Cruz; anti-GLUT1 
(ab15309), anti-GAPDH (6C5 ab8245), anti-myc (9E10 ab32) AbCam; anti-EGFR 
(LA22) Millipore. Alexa Fluor Phalloidin 647 (A22287) was from Thermo Scientific. 
EGF and HGF were from R&D, MK2206 was from Selleckchem, bafilomycin from 
Sigma and MG132 from Calbiochem. 
 
Immunohistochemistry 
Immunohistochemistry (IHC) was performed on a tissue microarray (TMA) of 1608 
consecutive BCs and 99 normal samples from the European Institute of Oncology in 
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Milan, Italy (years 1997-2000). Cases were annotated for clinical and pathological 
parameters and censored at 10 years from surgery. All tissues were collected via 
standard operating procedures approved by the Institutional Ethical Board, and 
informed consent was obtained for all tissue specimens linked with clinical data. 
 TMAs were stained in a Bond Max Automated IHC Vision Biosystem (Leica 
Microsystems) using the Bond Polymer Refine Detection Kit (DS9800). 3-μm-thick 
sections were prepared from formalin-fixed paraffin-embedded blocks, 
deparaffinized, pre-treated with the Epitope Retrieval Solution 1 (pH6) at 100°C for 
20 min and then incubated for 30 min with anti-USP6NL (Assay Biotech C19466), 
1:100 diluted in Bond Primary Antibody Diluent (AR9352) at final concentration of 10 
g/ml. Slides were acquired with the Aperio ScanScope system (Leica 
Microsystems). 
 
METABRIC analysis and statistics 
Sample extraction, processing and analysis of the METABRIC samples are 
described in (23). Differential expression was determined using the limma package 
(24) followed by survival distributions using the log rank test. Comparison between 
expression in the Integrative Cluster 10 and the rest of the METABRIC tumors was 
by two-sided t-test. Survival analysis was by Kaplan-Meier estimates; associations 
with diseases specific survival was determined by the log rank test for single factors 
or Cox multiple regression for multiple several factors. The Cox model was stratified 
by hospital and included tumor size, tumor grade, number of lymph nodes as 
numeric and the USP6NL copy number aberration as a binary variable. The 
increasing trend between copy number and expression was determined using the 
one-sided Jonckheere-Terpstra test from the R clinfun package. Statistical analysis 
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in the cell biology experiments was performed with the non-parametric Wilcoxon test, 
unpaired data significant levels < 0.02. 
 
Biochemical assays and Mesoscale analysis  
Total cell lysates were obtained with hot (95°C) lysis buffer (125 mM Tris HCl pH 6.8, 
2.5% SDS), separated on SDS-PAGE gradient gels (Invitrogen) and transferred to 
nitrocellulose membrane. Densitometry of immunoblots was performed using ImageJ 
(https://rsb.info.nih.gov/ij/): phospho-AKT and phospho-GSK3 signal were divided 
by the intensity of the corresponding total protein. GLUT1, phospho-EGFR, EGFR, 
phospho-MET and MET were normalized over HSP90 or GAPDH.  
 Multiplex phosphoproteomic analyses were as in (25) with commercially available 
plates [MAP kinase multiplex assay (K15101D) and phosphoSer(473)AKT/Total 
(K15100D)] MesoScale Discovery. Phospho-proteins signals, normalized over 
control, were converted in logarithmic form and represented with heat maps 
generated by the Gedas program. Measurements of endocytosis of surface 
biotinylated receptors with sulfo-NHS-SS-biotin (ThermoScientific) and assessment 
of surface GLUT1 with non cleavable biotin were performed by capture ELISA as in 
(25).  
 
Immunofluorescence and quantifications 
Immunofluorescence was performed as previously described (26). Primary 
antibodies were revealed by Alexa Fluor 555- and 488- conjugated antibodies.  In 
the GLUT1/EEA1 staining, permeabilization was in PBS 2% BSA, 0.1% saponin for 
30 min at RT. Incubation with primary and secondary antibodies was in PBS 0.2% 
BSA, 0.1% saponin. In the phospho-AKT/AKT total stainings, blocking and 
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permeabilization was in PBS 5% donkey serum, 0.3% Triton-X100.  Primary and 
secondary antibodies were diluted in PBS 0.3% Triton-X100. In the phospho-EGFR/ 
EGFR total stainings, blocking and permeabilization were in PBS 2% BSA, 0.02% 
saponin for 10 min at RT. Confocal analysis was performed with a Leica SP8 AOBS 
microscope. Colocalization between GLUT1 and EEA1 was measured with JacoP 
plugin of ImageJ. Because variability was recorded among experiments in total-AKT 
staining, the intensity of phospho-AKT was measured as the Pearson's correlation 
coefficient between phospho-AKT and Phalloidin provided by the LasAF software 
(Leica). Measurements of myc-GLUT1 endocytosis are detailed in figure legend. 
 
Cell count, glucose uptake and lactate production 
 Cells were counted by Trypan blue exclusion. Briefly, cells silenced or treated as 
indicated, were collected both from the medium and by trypsinizing the adherent 
ones. This was necessary since some of the BC cell lines growth either partially in 
suspension (HCC1187) or detach easily from adherence. Cells were resuspended in 
complete medium, diluted in Trypan blue solution and counted with a 
Bürker chamber. At least eight fields/sample were counted in multiple replicates. In 
the glucose deprivation assays, cells were starved in DMEM 10% FBS without D-
glucose and sodium pyruvate (A14430 Gibco). 
 Cell toxicity and ATP cell content were evaluated with the CellTox Green 
Citotoxicity Assay and CellTiter-Glo (Promega).  
 Glucose uptake was measured with the Glucose Uptake-Glo Assay (Promega). 
Cells were incubated for 10 minutes in glucose-deprived medium supplemented with 
1 mM 2-Deoxy-D-Glucose (2DG). Glucose uptake (fmol/cell/min) was calculated as 
follows:  
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Rate of glucose uptake = ([2DG6P] * (volume of sample)) / ((number of cells) * (time 
of uptake)). 
 Intracellular Lactate production was determined with the fluorimetric L-Lactate 
Assay Kit (Cayman). The same number of HCC70 and HCC1187 silenced cells were 
processed and the concentration (μM) of L-Lactate was determined as follows: 
 L‐Lactate (μM)= [CF-(y-intercept)
Slope
] * 2 * sample dilution 
CF is the corrected fluorescence (background subtracted), and slope and intercept 
were calculated from the standard reference curve.  
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RESULTS 
 
USP6NL is overexpressed in aggressive BCs 
We used the cBioPortal (27,28) to survey alterations affecting USP6NL in BC 
datasets. In the METABRIC cohort (23,29), high mRNA and gene amplification of 
USP6NL were detected in ~7% and ~3.5%, respectively (Figure 1A left). Around 
75% of all amplified cases also displayed mRNA up-regulation (Figure 1A left). 
Moreover, BCs with gains and copy number amplifications showed a proportional 
increase in USP6NL mRNA expression (Figure 1B). Similar results were obtained 
from the TCGA dataset (30) (Figure 1A right).  
 In the METABRIC cohort, expression of USP6NL was higher in the PAM50 Basal 
and Her2 subtypes vs. Luminal and Normal subtypes (p<0.0001) (Figure 1C). Using 
the genomic-based Integrative Cluster classification of BCs (31), we found that 
USP6NL expression was associated with the Integrative Cluster 10 (IntClust10, 
Supplementary Figure S1) which incorporates mostly triple-negative tumors and 
represents a high risk group.  
 In univariate analysis USP6NL copy number and expression was significantly 
associated with worse BC specific survival (HR 1.81; p<0.0001) (Figure 1D). This 
association remained significant in multivariable analysis (HR* 1.46; p<0.004) when 
grade, size and lymph nodes involvement were considered (Supplementary Table 1).  
 We investigated the expression of USP6NL in BCs also at the protein level by IHC 
on TMAs (Methods and Figure 1E). The normal mammary gland displayed 
heterogeneous staining of USP6NL, with levels comparatively higher in the luminal 
than in the basal layer (Figure 1E). USP6NL protein expression was, on average, 
higher in BC samples (p<0.0001). Strongest positivity (score 3) was found in 7% of 
BCs and never detected in normal samples (Figure 1F), concordant with the up-
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regulation at the mRNA level (Figure 1A). Also in this cohort, strong USP6NL 
expression correlated with aggressiveness (higher grade and increased percentage 
of Ki-67 positive cells) and with the molecular subtype of triple-negative BCs 
(Supplementary Table 2). In the IHC series we did not detect correlation with 
prognostic outcome likely because of a lower number of events in the USP6NL-high 
BCs in this cohort vs. the METABRIC one. 
 Altogether, these results suggest that USP6NL is a copy number driver gene in 
BCs. 
 
Overexpression of USP6NL in BC cells promotes proliferation and sustains 
AKT phosphorylation in a GAP-dependent manner 
To investigate the role of USP6NL elevation in BCs, we selected two USP6NL-high 
basal-like BC cell lines expressing high amount of the USP6NL protein, HCC70 and 
HCC1187, and two non-transformed, USP6NL-low, mammary cell lines, MCF10A 
and HMEC (Figure 2A). Silencing of USP6NL reduced proliferation in both the 
USP6NL-high lines, leaving the USP6NL-low cells unaffected (Figure 2A-B and 
Supplementary Figure S2A-B), arguing that USP6NL-high BC cells depend on this 
molecule for their optimal growth. The effects of the functional ablation of USP6NL 
on cell number were due to a decrease in the proliferation rate and not to increased 
cell death, as it will be subsequently shown. 
 USP6NL has been found to restrain EGFR endocytosis (17-19). Endocytosis and 
trafficking control the magnitude of the EGFR signaling (32), suggesting that 
USP6NL might affect proliferation by dampening intracellular signaling pathways. 
Thus, we analyzed alterations in the phosphorylation status of key signal 
transducers: AKT, ERK1/2, JNK and p38, by the MesoScale platform. USP6NL 
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depletion significantly reduced AKT phosphorylation in HCC70 and HCC1187 cells, 
but not in MCF10A (Figure 2C and Supplementary Figures S2B and S3A). Lesser 
changes in ERK1/2, JNK and p38 phosphorylation were also detected, albeit 
frequently not significant and not shared between the USP6NL-overexpressing BC 
cells (Figure 2C).  
 To validate the specificity of the effects, we performed rescue experiments. We 
generated stable inducible cell populations by infecting HCC70 cells with lentiviral 
vectors carrying the silencing-resistant version of USP6NL or its GAP-defective 
mutant R150 (19). Re-expression of the wild type protein in USP6NL-silenced cells 
rescued AKT activation and cell proliferation (Figure 2D-E). Conversely, re-
expression of R150 did not recover any of the phenotypes, revealing that the effects 
of USP6NL depend on its GAP function (Figure 2D-E). 
 Phosphorylation of AKT by PDK1 on Thr308 and by mTORC2 on Ser473 results 
in full AKT activation (33). USP6NL silencing similarly impaired both phosphorylation 
events, and the phosphorylation of the AKT substrate GSK3 in the overexpressing 
BC lines but not in MCF10A cells (Supplementary Figure S3A). 
 Finally, expression of the myristoylated, constitutive active, PI3K mutant (PI3KCA) 
(34) recovered AKT activation in USP6NL-silenced cells (Figure 2F). PI3KCA also 
rescued the defect caused by USP6NL depletion on cell proliferation (Figure 2G) 
suggesting that down modulation of the PI3K/AKT axis might account for this latter 
effect in the USP6NL-silenced BC cells.  
 
USP6NL depletion accelerates EGFR degradation downregulating AKT 
Since the GAP function of USP6NL inhibits EGFR endocytosis (17,19), and controls 
AKT activation (Figure 2D), we tested whether reduced phosphorylation of AKT in 
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USP6NL-silenced cells resulted from increased internalization and degradation of 
the EGFR. Depletion of USP6NL in the BC-overexpressing cell lines, but not in 
MCF10A or HMEC cells, accelerated EGFR degradation dampening both EGFR and 
AKT phosphorylation both at steady-state (Figure 3A) and upon EGF stimulation 
(Supplementary Figure S3B). Measurements of EGFR endocytosis confirmed that 
functional ablation of USP6NL in HCC70 cells increased the amount of internalized 
EGFR (Supplementary Figure S3C). Conversely, another RTK, the MET receptor, 
was largely unaffected by USP6NL silencing, suggesting some degree of specificity 
of USP6NL, within the limits of the tested conditions. In particular, total MET levels 
(Figure 3A) and receptor internalization (Supplementary Figure S3C) were not 
appreciably affected. Some, not significant, increase was detected in the levels of 
phospho-MET, not correlating with AKT phosphorylation or USP6NL levels. Together 
these results are compatible with the notion that overexpression of USP6NL delays 
EGFR endocytosis and degradation, thereby chronically activating AKT.  
 A likely downstream candidate for the effects of USP6NL in the described 
phenotypes is RAB5. USP6NL exerts GAP activity towards several Rabs (17-20), 
among these, RAB5 has been directly implicated in endocytic pathways and 
specifically in EGFR endocytosis (35,36). We tested, therefore, whether 
overexpression of RAB5 could phenocopy the ablation of USP6NL. This was indeed 
the case, as shown by reduced EGFR levels, and AKT phosphorylation (Figure 3B) 
implicating RAB5 as a probable downstream effector of USP6NL in the control of the 
analyzed phenotypes. 
 
USP6NL overexpression fuels aerobic glycolysis in BC cells by stabilizing the 
glucose transporter GLUT1 in an AKT-dependent manner 
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AKT controls cell proliferation, survival and metabolism (33). Thus, we looked at the 
ATP cell content and at the occurrence of cell death in the USP6NL-silenced cell 
lines. In these experiments, we introduced also a lung carcinoma cell line, H1299, 
which has little amount of USP6NL, to test the effects in a transformed background 
bearing low USP6NL levels (Supplementary Figure S4A-B). Depletion of USP6NL 
reduced the ATP cellular content in HCC70 and HCC1187, but not in USP6NL-low 
cells (Figure 4A) without causing significant differences in cell death, as measured 
by DNA accessibility (Figure 4B) suggesting a role for USP6NL in the metabolic 
control of cancer cell growth.  
 One of the best-characterized metabolic outcomes of the upregulation of AKT in 
cancer is increased aerobic glycolysis (37). In USP6NL-depleted BC lines, but not in 
USP6NL-low MCF10A and H1299 cells, we found a ~ 80% decrease in the rate of 
glucose uptake (Figure 5A). Similarly, lactate production was significantly reduced 
(Figure 5B). Finally, only the USP6NL-overexpressing BC cell lines were sensitive to 
glucose deprivation (Figure 5C). Notably, USP6NL depletion abrogated this 
phenotype (Figure 5C) indicating that the elevated glycolytic metabolism of these 
cells depends on the high USP6NL levels. 
 AKT stimulates the glycolytic capacity of cancer cells by increasing expression 
and targeting of GLUT1 to the PM, and by regulating key glycolytic enzymes (14-
16,37). In particular, AKT stabilizes GLUT1 at the PM by inhibiting its endocytosis 
(12,13). In agreement, we found that USP6NL depletion decreased the amount of 
GLUT1 in the overexpressing BC cell lines, but not in the USP6NL-low cells where, 
rather, an increment in the glucose transporter was observed (Figure 6A). Re-
expression of USP6NL, but not of R150, in the silenced HCC70 cells readily 
recovered GLUT1 levels showing that the latter depend on the GAP activity, hence – 
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most likely – on the endocytic/trafficking function of USP6NL (Figure 6B). In further 
support, treatment with the lysosomal blocking agent bafilomycin, but not with the 
proteasomal inhibitor MG132, rescued the levels of GLUT1 in USP6NL-silenced cells 
indicating that USP6NL stabilizes GLUT1 by inhibiting its trafficking-mediated 
degradation (Figure 6C). Finally, and in agreement with a GAP-dependent role for 
USP6NL in GLUT1 endocytosis and degradation, also overexpression of RAB5 
reduced GLUT1 levels (Figure 6D). 
 We analyzed whether the effect of USP6NL on GLUT1 stability are mediated by 
AKT. The expression of PI3KCA in the USP6NL-silenced HCC70 cells, along with 
the rescue of AKT phosphorylation (Figure 2F), also recovered GLUT1 expression 
(Figure 6E). In addition, treatment with the AKT inhibitor MK2206 resulted in GLUT1 
degradation, which was rescued by concomitant addition of bafilomycin, exclusively 
in the USP6NL-overexpressing BC cells (Figure 6F). Induction of GLUT1 
degradation in the HCC1187 cells required high inhibitor concentration. However, 
MK2206 did not cause GLUT1 degradation in the USP6NL-low cells, even at the 
highest concentration (Figure 6F). Altogether these data argue that increased 
USP6NL levels stabilize GLUT1 in an AKT dependent-manner. 
 Next, we tried to obtain evidence linking the stabilization of GLUT1 in USP6NL-
overexpressing cells to AKT-dependent inhibition of endocytosis of the transporter. 
We analyzed the dynamics of GLUT1 transport upon EGF stimulation in HMEC cells 
overexpressing USP6NL (USP6NLhigh) or its GAP mutant (R150high) (Figure 7A and 
Supplementary Figure S5A). In control HMEC, in the absence of stimulation (SF), 
GLUT1 mainly localized in intracellular compartments, partially overlapping with the 
early endosomal marker EEA1. Stimulation with EGF for 5 min caused significant 
redistribution to the PM and reduced co-localization with EEA1. When EGF was 
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removed to interrupt stimulation, GLUT1 re-localized to early endosomes. Similar 
dynamics were observed in HMEC-R150high cells. Conversely, in HMEC-USP6NLhigh, 
GLUT1 was predominantly at the PM under all conditions, including in serum starved 
cells, suggesting that increased USP6NL levels sustain basal AKT activation that, in 
turn, maintains GLUT1 at the cell surface. In support, we observed basal activation 
of AKT in serum starved USP6NLhigh cells (Supplementary Figure S6A-B). Moreover, 
consistent with data showing that AKT blockade prevents localization of glucose 
transporters to the PM (38), pre-treatment with MK2206 prompted GLUT1 removal 
from the surface in control and R150high cells stimulated with EGF as well as in the 
serum-starved USP6NLhigh cells (Figure 7B and Supplementary Figure S5A). The 
ability of USP6NL to interfere with GLUT1 endocytic dynamics was also confirmed 
by two additional approaches exploiting either a GLUT1 construct carrying an 
exofacial myc tag or surface biotinylation experiments (Supplementary Figure S5B-
C). Finally, similarly to USP6NL depletion, inhibition of AKT by MK2206 treatment 
impaired proliferation in the BC cell lines overexpressing USP6NL (Supplementary 
Figure S7). 
 In conclusion, our findings argue that high USP6NL levels stabilize GLUT1 in an 
AKT-dependent manner fostering aerobic glycolysis, and determine sensitivity to 
glucose deprivation in BC cells. 
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DISCUSSION  
 
Our study reveals a previously unrecognized crosstalk between endocytosis and 
metabolic reprogramming in BC relying on the overexpression of USP6NL. This 
event is likely to play a causal role in the natural history of BC, as USP6NL is 
frequently amplified/overexpressed in this cancer, in particular in basal-like tumors 
classified as IntClust10, and correlates with worse prognostic outcome. In addition, 
in vitro, the depletion of USP6NL impairs proliferation exclusively of BC cells 
overexpressing this protein and not of normal mammary cells. This suggests a 
degree of addiction of USP6NL-overexpressing BCs, pointing to this alteration as a 
relevant mechanism of signaling-metabolic rewiring. 
 Under basal conditions in BC cells that overexpress USP6NL, functional depletion 
of the latter promotes EGFR and AKT downregulation. We hypothesize that chronic 
USP6NL overexpression, by delaying EGFR endocytosis (probably by inhibiting the 
action of RAB5), stabilizes the receptor at the PM facilitating its activation and the 
ensuing recruitment of PI3K, eventually resulting in sustained AKT phosphorylation. 
This hypothesis is supported by the observation that ectopic expression of USP6NL 
in HMEC cells increases AKT phosphorylation even in absence of exogenous EGFR 
stimulation. Furthermore, USP6NL is mainly localized to the PM (19), a location 
where the PI3K/AKT signaling axis is generally considered to initiate (39). Finally, 
AKT phosphorylates the GLUT1 endocytic adaptor TXNIP at the PM, inhibiting the 
endocytosis of glucose transporters (40). Thus, the concerted action of USP6NL and 
AKT, acting at the cell surface, might link EGFR signaling to glucose uptake. 
 Similarly to the EGFR, also GLUT1 degradation is accelerated by USP6NL 
depletion, and by AKT inhibition through MK2206, only in USP6NL-overexpressing 
BC cells. Interestingly, MK2206 is an allosteric AKT inhibitor that prevents insulin-
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driven localization of GLUT1 to the PM and glucose uptake (38) but does not cause 
GLUT1 degradation in normal cells [this study and (38)]. In agreement, only cell lines 
overexpressing USP6NL are sensitive to AKT inhibition and glucose starvation. Of 
note, depletion of USP6NL abrogates sensitivity to glucose deprivation, in the same 
cell lines, further indicating that the high glycolytic capacity of these cells relies on 
USP6NL.  
 Based on the sum of our results, it is tempting to speculate that the poor 
prognostic outcome of BC patients carrying high USP6NL copy number might be 
related to the ability of USP6NL to promote glycolysis. Indeed, elevation of glycolysis 
is generally associated with tumor aggressiveness and poor prognosis, and is a 
distinguishing feature of a subset of basal-like BCs (2,3). Interestingly, in many 
instances, upregulation of glycolysis in tumors occurs through 
overexpression/stabilization of GLUT1, an alteration that correlates with 
aggressiveness (41-45). In this context, our data argue that the 
amplification/overexpression of USP6NL might be a mechanism of metabolic 
adaptation/fitness for some BCs. If so, USP6NL overexpression might represent a 
point of metabolic vulnerability for a subset of aggressive basal-like breast tumors.  
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Figure 1. USP6NL overexpression in BC 
A) Venn diagrams showing the number of cases harboring increased USP6NL copy 
number (AMP, red) and mRNA overexpression (UP-REG, black) in the METABRIC 
(left) and TCGA (right) datasets. p, p-value of the association between the indicated 
variables by Fisher's exact test. B) Correlation between USP6NL copy number and 
mRNA levels in the METABRIC samples (N=1974). DEL=copy number deletion, 
NEUT=copy number neutral, GAIN= copy number gain, AMP=copy number 
amplification; association between AMP and mRNA expression p<0.0001. C) 
USP6NL mRNA levels in the Pam50 molecular subtypes in the METABRIC dataset. 
N= normal breast tissue, Norm= Normal-like, LumA= luminal A, LumB= luminal B, 
Her2= Her2 amplified, Basal= basal-like; correlation between overexpression and 
Basal tumors p<0.0001.  D) Kaplan-Meir plots showing the disease-specific survival 
in patients with (gain) or without (neutral/loss) copy number gain in the METABRIC 
dataset. HR, hazard ratio univariate gain vs. neutral/loss. HR*, hazard ratio 
multivariable gain vs. neutral/loss. E) Representative images of USP6NL protein 
expression by IHC in TMA cores and their relative score. F) Distribution of USP6NL 
protein expression according to the IHC score in normal breast tissue (99 samples) 
and BCs (1608 samples). 
 
Figure 2. USP6NL depletion impairs AKT phosphorylation and cell proliferation 
in USP6NL-overexpressing BC cells  
A) Lysates from the indicated cell lines were silenced with control oligos (siCTR) or 
USP6NL oligo (siUSP6NL) and immunoblotted as indicated. B) Cell counts, after 2 
days of growth of HCC70, HCC1187, MCF10A and HMEC cell lines silenced as in 
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the legend. Normalization was performed vs. control in each cell line (siCTR = 1). 
Means  s.e.m. from at least 4 independent experiments, each including at least 4 
technical replicates. C) Heat maps of phosphoprotein levels in the indicated cell lines 
silenced or not for USP6NL. The color scale bar represents log2 phosphoprotein 
levels, relative to control (three independent experiments performed in duplicates). 
Phospho-AKT p<0.0001 in HCC70 and <0.002 in HCC1187 cells; pJNK p<0.0002 in 
HCC1187 and <0.002 in MCF10A cells. D) Stable doxy-inducible HCC70 cell 
populations carrying silencing-resistant USP6NL or the R150 mutant were silenced 
as indicated on top (siCTR or siUSP6NL), and treated (+) or not (-) with doxycycline 
for 48 hours to re-express USP6NL or R150. Lysates were immunoblotted as 
indicated. Densitometric analysis of pAKT/AKT tot is reported underneath. Means  
s.e.m. n=4. Membranes here and in the following Figures, unless otherwise 
indicated, were first immunoblotted with anti-phospho antibodies, stripped and re-
probed with anti-total antibodies. E) Cell counts in the inducible HCC70 populations 
silenced and treated as in D and indicated in the legend. Means  s.e.m. n=6; at 
least 3 technical replicates. F) Lysates from HCC70 cells stably expressing the 
myristoylated PI3KCA mutant (PI3KCA), or empty vector (mock), were silenced as 
indicated on top, and immunoblotted as indicated. Densitometric analysis of 
pAKT/AKT tot is reported underneath. Means  s.e.m. n=6. G) Cell counts for the 
cellular populations transfected and silenced as in F. Means  s.e.m. n=5; 4 
technical replicates.  
 
Figure 3. USP6NL depletion accelerates EGFR down regulation in the 
overexpressing BC cells  
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A) Left. Lysates from the indicated cell lines were silenced as on top, followed by 
immunoblotting as shown. Right. Densitometric analyses. Means  s.e.m. of at least 
3 experiments. B) Stable doxy-inducible MCF10A cell populations carrying the empty 
vector (CTR) or RAB5 (RAB5) were treated with doxycycline for 48 hours to 
overexpress RAB5. Total lysates were immunoblotted as on the right. Densitometric 
analysis is reported on the right. Mean ± s.e.m n=3.  
 
Figure 4. USP6NL silencing decreases the ATP cell content in the 
overexpressing BC cells without causing cell death 
A-B) The indicated cell lines were silenced as shown in the legend. A) 
Bioluminescent ATP cell content normalized to siCTR for each cell line (=1). Means 
± s.e.m. from at least 3 independent experiments each point done at least in 
duplicate. B) Mean fluorescence intensity of the toxicity marker CellTox green ± 
s.e.m. n=3 each in technical duplicates.  
 
Figure 5. USP6NL overexpression in BC cells controls their glycolytic 
metabolism 
A) Rate of glucose uptake in the indicated cell lines, silenced as in the legend. 
Means ± s.e.m. n=3 each in technical duplicates. B) L-Lactate production in HCC70 
and HCC1187 silenced as in the legend. Means ± s.e.m. n=3 each in technical 
triplicates. C) Sensitivity to glucose deprivation. The indicated cell lines, silenced as 
in the legend, were grown in complete medium (c.m.) or in medium without glucose 
(w/o) for 24 hours. Cell counts were normalized vs. their corresponding control in 
c.m. Means ± s.e.m. n=4; 4 technical replicates. 
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Figure 6. USP6NL prevents GLUT1-degradation in an AKT-dependent manner  
A) The indicated cell lines were silenced with control (siCTR) or USP6NL 
(siUSP6NL) oligos, followed by immunoblotting as indicated. GLUT1 migrates as a 
broad band at slightly different molecular weights in the various cell lines. B) Stable 
doxy-inducible HCC70 cells carrying silencing-resistant USP6NL or R150 mutant 
were silenced as indicated on top and treated (+) or not (-) with doxycycline for 48 
hours to re-express USP6NL or R150. Lysates were immunoblotted as shown on the 
right. C) HCC70 cells, silenced as indicated on top, were treated with DMSO, or 
bafilomycin (30 nM) or with MG132 (1 μM) for 2 hours. Lysates were immunoblotted 
as on the right. D) Doxy-inducible MCF10A cell populations carrying the empty 
vector (CTR) or RAB5 (RAB5) were treated with doxycycline for 48 hours to 
overexpress RAB5 followed by immunoblotting as indicated. E) Lysates from HCC70 
cells stably infected with the empty vector (mock) or with the PI3KCA mutant 
(PI3KCA) and silenced as on top were immunoblotted as on the right. F) Total 
cellular lysates from the cell lines shown on top treated O/N with DMSO (-) or with 
MK2206 (+) were immunoblotted as shown. HCC70 and HCC1187 cells were also 
treated with the combination MK2206 + bafilomycin. In all panels, densitometric 
analyses of GLUT1 levels are shown underneath as mean ± s.e.m. In A, B, E, and F, 
n=3; in C and D, n=4. 
 
Figure 7. High USP6NL inhibits AKT-dependent GLUT1 endocytosis  
A) Stable doxy-inducible HMEC cell populations were treated with doxycycline for 48 
hours to overexpress HA-tagged USP6NL (USP6NLhigh) or R150 (R150high). CTR are 
cells infected with the empty vector. Cells were serum starved O/N (SF) and then 
treated with 100 ng/ml of EGF for 5 min at 37°C (EGF). The ligand was then 
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removed by washing and cells were further incubated at 37°C for 15 min (EGF 
removal 15 min) before fixation. Confocal images show GLUT1 (green), EEA1 (red), 
or HA (black and white). In the top rows merged GLUT1 and EEA1 channels are 
shown and the boxed regions are magnified in the insets underneath (individual 
channels and merged). B) The indicated cells were treated with 1 μM MK2206 for 2 
hours and EGF (100 ng/ml) was added to control and R150high cells 5 min before 
fixation. Staining as in A. Bar in (A) and (B), 10 μm. A quantitative analysis of data in 
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